Researchers assessed whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation followed by a switch to a direct oral anticoagulant was effective and safe.
Researchers sought to determine the link between lung ultrasound findings and the development of VTE in patients with COVID-19.
Hospitalized patients with COVID-19 had a greater than 3-fold adjusted risk for venous thromboembolism compared with matched controls, the study found.
Scare utilization of guideline-recommended risk stratification tools has been noted in computed tomography pulmonary angiography in the emergency department.
A high prevalence of pulmonary embolism has been reported among patients with COVID-19 at the time of hospital admission.
Although the mortality of patients with high-risk pulmonary embolism has decreased over time, the decrease cannot be attributed to improved treatments for pulmonary embolism.
Patients with COPD who were hospitalized for acutely worsening respiratory symptoms had a prevalence of pulmonary embolism of 5.9%.
Critically ill patients with COVID-19 who experience concurrent pulmonary embolism do not have increased mortality compared with patients without pulmonary embolism.
The American Society of Hematology released evidence-based guidelines for the treatment of DVT and PE in patients without cancer.
Although hypercoagulability has been reported in critically ill patients with COVID-19, results from a small study revealed that these patients did not have a higher prevalence of pulmonary embolism compared to patients without COVID-19.
